The 36-month beta value for RCUS is at 0.89. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RCUS is 48.50M, and currently, shorts hold a 14.37% of that float. The average trading volume for RCUS on September 02, 2024 was 714.46K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RCUS) stock’s latest price update
Arcus Biosciences Inc (NYSE: RCUS) has seen a decline in its stock price by -1.21 in relation to its previous close of 17.33. However, the company has experienced a -4.94% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-08-26 that HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company’s common stock at an exercise price per share of $18.01, which was the closing price on August 23, 2024, and.
RCUS’s Market Performance
Arcus Biosciences Inc (RCUS) has experienced a -4.94% fall in stock performance for the past week, with a 8.98% rise in the past month, and a 13.60% rise in the past quarter. The volatility ratio for the week is 4.45%, and the volatility levels for the past 30 days are at 6.03% for RCUS. The simple moving average for the past 20 days is 6.49% for RCUS’s stock, with a 4.81% simple moving average for the past 200 days.
Analysts’ Opinion of RCUS
Many brokerage firms have already submitted their reports for RCUS stocks, with BofA Securities repeating the rating for RCUS by listing it as a “Neutral.” The predicted price for RCUS in the upcoming period, according to BofA Securities is $33 based on the research report published on November 18, 2022 of the previous year 2022.
Morgan Stanley, on the other hand, stated in their research note that they expect to see RCUS reach a price target of $40. The rating they have provided for RCUS stocks is “Overweight” according to the report published on October 11th, 2022.
BTIG Research gave a rating of “Buy” to RCUS, setting the target price at $57 in the report published on October 15th of the previous year.
RCUS Trading at 10.28% from the 50-Day Moving Average
After a stumble in the market that brought RCUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.51% of loss for the given period.
Volatility was left at 6.03%, however, over the last 30 days, the volatility rate increased by 4.45%, as shares surge +13.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.74% upper at present.
During the last 5 trading sessions, RCUS fell by -4.94%, which changed the moving average for the period of 200-days by +27.48% in comparison to the 20-day moving average, which settled at $16.18. In addition, Arcus Biosciences Inc saw -10.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCUS starting from Azoy Alexander, who sale 1,357 shares at the price of $14.97 back on Aug 13 ’24. After this action, Azoy Alexander now owns 19,070 shares of Arcus Biosciences Inc, valued at $20,314 using the latest closing price.
Jarrett Jennifer, the Chief Operating Officer of Arcus Biosciences Inc, sale 11,551 shares at $17.55 during a trade that took place back on Mar 27 ’24, which means that Jarrett Jennifer is holding 215,253 shares at $202,720 based on the most recent closing price.
Stock Fundamentals for RCUS
Current profitability levels for the company are sitting at:
- -1.19 for the present operating margin
- 0.95 for the gross margin
The net margin for Arcus Biosciences Inc stands at -1.01. The total capital return value is set at -0.3. Equity return is now at value -41.47, with -20.70 for asset returns.
Based on Arcus Biosciences Inc (RCUS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -22.45.
Currently, EBITDA for the company is -291.0 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 5.75. The receivables turnover for the company is 7.48for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.14.
Conclusion
In conclusion, Arcus Biosciences Inc (RCUS) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
